Cafepharma Today

June 5 2025 - GLP-1 drugs may be linked to elevated risk of serious eye disease, study finds
GLP-1 drugs may be linked to elevated risk of serious eye disease, study finds
Bispecific cancer drugs, data caveats and funding alarms: 3 takeaways from ASCO
FDA’s Elsa AI is here, and the industry has questions
Merck gains U.S. patent office support in Keytruda dispute
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Bristol-Myers, Otsuka's Schizophrenia Drug Backed for Teens by U.K. Agency
Bloomberg
Wednesday, December 1, 2010 - 8:08am
tags:
Bristol-Myers Squibb, Otsuka, schizophrenia, aripiprazole, UK, Abilify
Novartis will eliminate 1,400 US sales jobs
Yahoo/AP
Wednesday, December 1, 2010 - 7:22am
tags:
Novartis, layoffs, drug reps
Good News for Spectrum Pharma
Yahoo/Zacks.com
Wednesday, December 1, 2010 - 7:21am
tags:
Spectrum Pharmaceuticals, Fusilev, Pfizer, Sanofi, colorectal cancer
Pfizer awards $2M to cancer network
Bizjournals.com
Wednesday, December 1, 2010 - 7:19am
tags:
Pfizer, cancer, philanthropy
Incoming Merck chief to focus on pricing
FT.com
Wednesday, December 1, 2010 - 7:18am
tags:
Merck, Pharma CEOs, pricing, Kenneth Frazier
FDA disputes prostate drugs' risk-cutting power
Fierce Pharma
Tuesday, November 30, 2010 - 10:59am
tags:
FDA, GSK, prostate cancer, Avodart, Merck, Proscar
Drug groups face new generics threat
FT.com
Tuesday, November 30, 2010 - 10:57am
tags:
generics, Roche, Merck, JNJ, Abbott Laboratories, biogenerics
Is a Revenue Miss Coming for Eli Lilly?
Motley Fool
Tuesday, November 30, 2010 - 10:54am
tags:
Eli Lilly
Aegerion Pharma 3Q loss widens on higher costs
Yahoo/AP
Tuesday, November 30, 2010 - 10:53am
tags:
earnings, Aegerion
RNAi Is On Sale
Motley Fool
Tuesday, November 30, 2010 - 10:52am
tags:
RNAi, Merck, Alnylam, Pfizer, Amgen, Novartis, Eli Lilly, Roche
Biotech Calendar: Key Dates for December
TheStreet.com
Tuesday, November 30, 2010 - 9:20am
tags:
Delcath, Arena Pharmaceuticals, RXi Pharmaceuticals, Cell Therapeutics, Amgen, Incyte, Celgene, Corcept Therapeutics, Affymax, Targacept, Exelixis, Orexigen, ONYX Pharmaceuticals, Seattle Genetics, MannKind, Alimera, AstraZeneca, Human Genome Sciences
Keryx drug candidate meets late-stage study goal
Yahoo/AP
Tuesday, November 30, 2010 - 9:16am
tags:
Keryx, ZerenaxT
Merck Names Kenneth Frazier CEO, Clark Stays as Chairman
Bloomberg
Tuesday, November 30, 2010 - 9:15am
tags:
Merck, Pharma CEOs, Kenneth Frazier
House Passes ‘Doc Fix’; Medicare Cuts Now Due to Kick in Jan. 1
WSJ Online
Tuesday, November 30, 2010 - 8:03am
tags:
Medicare, physicians, healthcare reform
Orexigen: Contrave FDA Panel Preview
TheStreet.com
Tuesday, November 30, 2010 - 8:02am
tags:
FDA, advisory panels, Orexigen, Contrave, obesity, Arena Pharmaceuticals, Vivus
Inhibitex: A Biotech Gem in the Enormous Hepatitis C Market
Seeking Alpha
Tuesday, November 30, 2010 - 7:59am
tags:
Inhibitex, hepatitis C, Pharmasset, Vertex Pharmaceuticals
Drug Maker Wrote Book Under 2 Doctors’ Names, Documents Say
NY Times, NY
Tuesday, November 30, 2010 - 7:56am
tags:
GSK, physician payments, Ghostwriting
Drugmaker Endo Diversifies Its Product Lineup Through Acquisitions
Investors.com
Monday, November 29, 2010 - 8:04pm
tags:
Endo, diversification
Here's How Teva Pharmaceutical May Be Failing You
Motley Fool
Monday, November 29, 2010 - 8:03pm
tags:
Teva Pharmaceuticals, Pfizer, Elan, Abbott Laboratories
5 Biotechs Investors Should Be Watching
Seeking Alpha
Monday, November 29, 2010 - 6:05pm
tags:
Amarin, Cyclacel, Neoprobe, Inhibitex, Repligen

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Not One of Your Easy Crystals
In the Pipeline
The Continuing Crisis, Part XV: The Horrendous Trump Budget
In the Pipeline
Taurine Revisited
In the Pipeline
A New Route to Asthma Treatment - Through the Liver, of All Places
In the Pipeline
One Drug's Supply Chain, In Detail
In the Pipeline
A Reaction to Alzheimer's Fraud
In the Pipeline
Whoa Now: Cautionary Tales from Materials Science
In the Pipeline
Inside a Scientific Paper Mill
In the Pipeline
Autoimmune Disease, Transformed?
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.